A randomized, double-blind, single-dose study (LAVENDER) to assess the safety, tolerability, and immunogenicity of ABP 980 and pertuzumab combined in a single infusion in healthy subjects - V. Hanes; V. Chow; T. Stewart; A. Puri (Breast, 2021)